Repurposing Sitagliptin for COVID-19 in Adults: Clinical Benefits and An Approach for the Mechanism
Yıl: 2022 Cilt: 27 Sayı: 2 Sayfa Aralığı: 324 - 334 Metin Dili: İngilizce DOI: 10.5578/flora.20229816 İndeks Tarihi: 10-08-2022
Repurposing Sitagliptin for COVID-19 in Adults: Clinical Benefits and An Approach for the Mechanism
Öz: Introduction: Dipeptidyl peptidase-4 (DPP4) has been shown to be a functional receptor for MERS-CoV. An interaction between the viral spike protein and DPP4 is thought to facilitate viral entry. We aimed to find out whether sitagliptin, a member of DPP4 inhibitors, would have beneficial effects in COVID-19 patients. Materials and Methods: In this single center retrospective study, we evaluated 58 patients of whom 16 were on sitagliptin treatment. Molecular docking studies were performed to identify possible interactions between ACE2 and sitagliptin. Results: Sitagliptin use shortened the time to clinical recovery about 3.5 and fastened viral clearance more than 5 days. Resolution of all symptoms was achieved on a mean±standard error (SE) of 2.50 ± 0.40 days in sitagliptin (+) group and 5.69 ± 0.61 days in sitagliptin (-) group (Log-rank test, p< 0.001). PCR tests for SARS-CoV-2 resulted negative in mean ± SE of 7.50 ± 0.98 days in sitagliptin (+) and 13.17 ± 1.07 days in sitagliptin (-) group (Log-rank test, p= 0.003). Compared to day 0, CRP, ferritin and D-dimer levels on days three, five, and seven were significantly lower whereas lymphocyte count was higher in sitagliptin (+) group. Conclusion: Our results suggest that sitagliptin seems to have a potential to be considered for the treatment of COVID-19.
Anahtar Kelime: Yetişkinlerde COVID-19 Tedavisi Için Sitagliptin Kullanılması: Klinik Faydalar ve Mekanizma Yaklaşımı
Öz: Giriş: Dipeptidil peptidaz-4’ün (DPP4) MERS-CoV için fonksiyonel bir reseptör olduğu gösterilmiştir. Viral spike proteini ve DPP4 arasındaki etkileşimin viral girişi kolaylaştırdığı düşünülmektedir. Biz de bu çalışmada DPP4 inhibitörlerinin bir üyesi olan sitagliptinin COVID- 19 hastalarında faydalı etkileri olup olmayacağını öğrenmeyi amaçladık. Materyal ve Metod: Bu tek merkezli retrospektif çalışmada, 16’sı sitagliptin tedavisi almakta olan 58 hastayı değerlendirdik. ACE2 ve sitagliptin arasındaki olası etkileşimleri belirlemek için moleküler yerleştirme (docking) çalışmaları yaptık. Bulgular: Sitagliptin kullanımı klinik iyileşme süresini yaklaşık 3.5 gün kısalttı ve viral klirensi beş günden fazla hızlandırdı. Tüm semptomların düzelmesi, sitagliptin (+) grubunda 2.50 ± 0.40 gün ve sitagliptin (-) grubunda 5.69 ± 0.61 gün ortalama ± standart hata (SE) ile sağlandı (Log-rank testi, p< 0.001). SARS-CoV-2 için PCR testleri, sitagliptin (+) grubunda 7.50 ± 0.98 gün ve sitagliptin (-) grubunda 13.17 ± 1.07 gün ortalama ± SE’de negatif sonuçlandı (Log-rank testi, p= 0.003). Sitagliptin (+) grubunda 0. güne göre üçüncü, beşinci ve yedinci günlerde CRP, ferritin ve D-dimer düzeyleri anlamlı olarak düşük, lenfosit sayısı ise daha yüksekti. Sonuç: Sonuçlarımız, sitagliptinin COVID-19 tedavisi için düşünülme potansiyeline sahip olduğunu gösterdi.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Chen Y, Liu Q, Guo D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. J Med Virol 2020;92(4):418-23. https://doi.org/10.1002/jmv.25681
- 2. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;579(7798):270-3. https:// doi.org/10.1038/s41586-020-2012-7
- 3. Gheblawi M, Wang K, Viveiros A, Nguyen Q, Zhong JC, Turner AJ, et al. Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: Celebrating the 20th anniversary of the discovery of ACE2. Circ Res 2020;126(10):1456-74. https://doi.org/10.1161/ CIRCRESAHA.120.317015
- 4. Li MY, Li L, Zhang Y, Wang XS. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. Infect Dis Poverty 2020;9(1):45. https://doi.org/10.1186/ s40249-020-00662-x
- 5. Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol 2019;17(3):181-92. https:// doi.org/10.1038/s41579-018-0118-9
- 6. Vankadari N, Wilce JA. Emerging WuHan (COVID-19) coronavirus: Glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26. Emerg Microbes Infect 2020;9(1):601-4. https://doi.org/10.1080 /22221751.2020.1739565
- 7. Rohrborn D, Wronkowitz N, Eckel J. DPP4 in Diabetes. Front Immunol 2015;6:386. https://doi.org/10.3389/fimmu. 2015.00386
- 8. Al-Qahtani AA, Lyroni K, Aznaourova M, Tseliou M, Al-Anazi MR, Al-Ahdal MN, et al. Middle east respiratory syndrome corona virus spike glycoprotein suppresses macrophage responses via DPP4-mediated induction of IRAK-M and PPARgamma. Oncotarget 2017;8(6):9053-66. https://doi. org/10.18632/oncotarget.14754
- 9. Editorial. COVID-19: underlying metabolic health in the spotlight. The Lancet Diabetes Endo 2020;8(6):P457. https:// doi.org/10.1016/S2213-8587(20)30164-9
- 10. Towler P, Staker B, Prasad SG, Menon S, Tang J, Parsons T et al. ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis. J Biol Chem 2004;279(17):17996-8007. https://doi. org/10.1074/jbc.M311191200
- 11. Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 2020; 581 (7807): 215-220. https://doi.org/10.1038/s41586-020-2180-5
- 12. Moruzzi P, Doria E, Agostoni PG, Capacchione V, Sganzerla P. Usefulness of L-thyroxine to improve cardiac and exercise performance in idiopathic dilated cardiomyopathy. Am J Card 71994;3(5):374-8. https://doi.org/10.1016/0002- 9149(94)90011-6
- 13. O’Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, Hutchison GR et al. Open Babel: An open chemical toolbox. J Cheminform 2011;3:33. https://doi. org/10.1186/1758-2946-3-33
- 14. Dallakyan S, Olson AJ. Small-molecule library screening by docking with PyRx. Methods Mol Biol 2015;1263:243-250. https://doi.org/10.1007/978-1-4939-2269-7_19
- 15. Rott O, Olson AJ. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 2010;31:455-61. https://doi.org/10.1002/jcc.21334
- 16. Dassault Systèmes BIOVIA SD. Discovery Studio Academic Free. 2020.
- 17. Solerte SB, D’Addio F, Trevisan R, Lovati E, Rossi A, Pastore I, et al. Sitagliptin treatment at the time of hospitalization was associated with reduced mortality in patients with Type 2 diabetes and COVID-19: A multicenter, case- control, retrospective, observational study. diabetes care 2020;dc201521. https://doi.org/10.2337/figshare. 12907490.v1
- 18. Nauck MA, Meier JJ. Reduced COVID-19 mortality with sitagliptin treatment? weighing the dissemination of potentially lifesaving findings against the assurance of high scientific standards. Diabetes Care 2020;43(12):2906-9. https://doi.org/10.2337/dci20-0062
- 19. Mirani M, Favacchio G, Carrone F, Betella N, Biamonte E, Morenghi E, et al. Impact of comorbidities and glycemia at admission and dipeptidyl peptidase 4 İnhibitors in patients with Type 2 diabetes with COVID-19: A case series from an academic hospital in lombardy, Italy. Diabetes Care 2020;dc201340. https://doi.org/10.2337/figshare. 12980015.v1
- 20. Emral R, Haymana C, Demirci I, Tasci I, Sahin M, Cakal E, et al. Lower COVID-19 mortality in patients with type 2 diabetes mellitus taking dipeptidyl peptidase-4 inhibitors: Results from a Turkish nationwide study. Diabetes Therapy 2021;12(11):2857-70. https://doi.org/10.1007/s13300- 021-01133-8
- 21. The effect of sitagliptin treatment in COVID-19 positive diabetic patients (SIDIACO). ClinicalTrial.gov. Identifier: NCT04365517, University of Milan, first posted April 28, 2020.
- 22. CDC Groups at Higher Risk for Severe Illness, Available from: https://www.cdc.gov/coronavirus/2019-ncov/need- extra-precautions/groups-at-higher-risk.html. Accessed 21 December 2020.
- 23. Bardaweel SK, Hajjo R, Sabbah DA. Sitagliptin: A potential drug for the treatment of COVID-19? Acta Pharm 2021;71(2):175-84. https://doi.org/10.2478/acph-2021- 0013
- 24. Seong JM, Yee J, Gwak HS. Dipeptidyl peptidase-4 inhibitors lower the risk of autoimmune disease in patients with type 2 diabetes mellitus: A nationwide population-based cohort study. Br J Clin Pharmacol 2019;85(8):1719-27. https:// doi.org/10.1111/bcp.13955
- 25. Kawasaki T, Chen W, Htwe YM, Tatsumi K, Dudek SM. DPP4 inhibition by sitagliptin attenuates LPS-induced lung injury in mice. Am J Physiol Lung Cell Mol Physiol 2018;315(5):L834-L845. https://doi.org/10.1152/ajplung. 00031.2018
- 26. Soare A, Gyorfi HA, Matei AE, Dees C, Rauber S, Wohlfart T, et al. Dipeptidylpeptidase 4 as a marker of activated fibroblasts and a potential target for the treatment of fibrosis in systemic sclerosis. Arthritis Rheumatol 2020;72(1):137-49. https://doi.org/10.1002/art.41058
- 27. Jose RJ, Manuel A. Correspondance: COVID-19 cytokine storm: The interplay between inflammation and coagulation. The Lancet Respiratory Medicine 2020;8(6):e46-e47. https://doi.org/10.1016/S2213-2600(20)30216-2
- 28. Tan L, Wang Q, Zhang D, Ding J, Huang Q, Tang YQ, et al. Correction: Lymphopenia predicts disease severity of COVID- 19: A descriptive and predictive study. Signal Transduct Target Ther 2020;5:61. https://doi.org/10.1038/s41392- 020-0159-1
- 29. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020;180(7):934-43. https://doi.org/10.1001/jamainternmed.2020.0994
- 30. Ling Y, Xu SB, Lin YX, Tian D, Zhu ZQ, Dai FH, et al. Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients. Chin Med J (Engl) 2020;133(9):1039-43. https://doi.org/10.1097/ CM9.0000000000000774
| APA | CINAR G, yazgan c, ELHAN A, Akdemir Kalkan İ, Gülten E, UNAL M, Demir Ö, Birengel S, Karahan Z, NAZIR H, Azap A (2022). Repurposing Sitagliptin for COVID-19 in Adults: Clinical Benefits and An Approach for the Mechanism. , 324 - 334. 10.5578/flora.20229816 |
| Chicago | CINAR GULE,yazgan coşkun,ELHAN ATİLLA HALİL,Akdemir Kalkan İrem,Gülten Ezgi,UNAL Mehmet Altay,Demir Özgür,Birengel Serhat,Karahan Zeynep Ceren,NAZIR HASAN,Azap Alpay Repurposing Sitagliptin for COVID-19 in Adults: Clinical Benefits and An Approach for the Mechanism. (2022): 324 - 334. 10.5578/flora.20229816 |
| MLA | CINAR GULE,yazgan coşkun,ELHAN ATİLLA HALİL,Akdemir Kalkan İrem,Gülten Ezgi,UNAL Mehmet Altay,Demir Özgür,Birengel Serhat,Karahan Zeynep Ceren,NAZIR HASAN,Azap Alpay Repurposing Sitagliptin for COVID-19 in Adults: Clinical Benefits and An Approach for the Mechanism. , 2022, ss.324 - 334. 10.5578/flora.20229816 |
| AMA | CINAR G,yazgan c,ELHAN A,Akdemir Kalkan İ,Gülten E,UNAL M,Demir Ö,Birengel S,Karahan Z,NAZIR H,Azap A Repurposing Sitagliptin for COVID-19 in Adults: Clinical Benefits and An Approach for the Mechanism. . 2022; 324 - 334. 10.5578/flora.20229816 |
| Vancouver | CINAR G,yazgan c,ELHAN A,Akdemir Kalkan İ,Gülten E,UNAL M,Demir Ö,Birengel S,Karahan Z,NAZIR H,Azap A Repurposing Sitagliptin for COVID-19 in Adults: Clinical Benefits and An Approach for the Mechanism. . 2022; 324 - 334. 10.5578/flora.20229816 |
| IEEE | CINAR G,yazgan c,ELHAN A,Akdemir Kalkan İ,Gülten E,UNAL M,Demir Ö,Birengel S,Karahan Z,NAZIR H,Azap A "Repurposing Sitagliptin for COVID-19 in Adults: Clinical Benefits and An Approach for the Mechanism." , ss.324 - 334, 2022. 10.5578/flora.20229816 |
| ISNAD | CINAR, GULE vd. "Repurposing Sitagliptin for COVID-19 in Adults: Clinical Benefits and An Approach for the Mechanism". (2022), 324-334. https://doi.org/10.5578/flora.20229816 |
| APA | CINAR G, yazgan c, ELHAN A, Akdemir Kalkan İ, Gülten E, UNAL M, Demir Ö, Birengel S, Karahan Z, NAZIR H, Azap A (2022). Repurposing Sitagliptin for COVID-19 in Adults: Clinical Benefits and An Approach for the Mechanism. Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi, 27(2), 324 - 334. 10.5578/flora.20229816 |
| Chicago | CINAR GULE,yazgan coşkun,ELHAN ATİLLA HALİL,Akdemir Kalkan İrem,Gülten Ezgi,UNAL Mehmet Altay,Demir Özgür,Birengel Serhat,Karahan Zeynep Ceren,NAZIR HASAN,Azap Alpay Repurposing Sitagliptin for COVID-19 in Adults: Clinical Benefits and An Approach for the Mechanism. Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi 27, no.2 (2022): 324 - 334. 10.5578/flora.20229816 |
| MLA | CINAR GULE,yazgan coşkun,ELHAN ATİLLA HALİL,Akdemir Kalkan İrem,Gülten Ezgi,UNAL Mehmet Altay,Demir Özgür,Birengel Serhat,Karahan Zeynep Ceren,NAZIR HASAN,Azap Alpay Repurposing Sitagliptin for COVID-19 in Adults: Clinical Benefits and An Approach for the Mechanism. Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi, vol.27, no.2, 2022, ss.324 - 334. 10.5578/flora.20229816 |
| AMA | CINAR G,yazgan c,ELHAN A,Akdemir Kalkan İ,Gülten E,UNAL M,Demir Ö,Birengel S,Karahan Z,NAZIR H,Azap A Repurposing Sitagliptin for COVID-19 in Adults: Clinical Benefits and An Approach for the Mechanism. Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi. 2022; 27(2): 324 - 334. 10.5578/flora.20229816 |
| Vancouver | CINAR G,yazgan c,ELHAN A,Akdemir Kalkan İ,Gülten E,UNAL M,Demir Ö,Birengel S,Karahan Z,NAZIR H,Azap A Repurposing Sitagliptin for COVID-19 in Adults: Clinical Benefits and An Approach for the Mechanism. Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi. 2022; 27(2): 324 - 334. 10.5578/flora.20229816 |
| IEEE | CINAR G,yazgan c,ELHAN A,Akdemir Kalkan İ,Gülten E,UNAL M,Demir Ö,Birengel S,Karahan Z,NAZIR H,Azap A "Repurposing Sitagliptin for COVID-19 in Adults: Clinical Benefits and An Approach for the Mechanism." Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi, 27, ss.324 - 334, 2022. 10.5578/flora.20229816 |
| ISNAD | CINAR, GULE vd. "Repurposing Sitagliptin for COVID-19 in Adults: Clinical Benefits and An Approach for the Mechanism". Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi 27/2 (2022), 324-334. https://doi.org/10.5578/flora.20229816 |
